Genome at 10: Scientists urge patience for medical breakthroughs

April 1, 2010 by Richard Ingham
This undated illustration shows the DNA double helix. The genome has yet to deliver on promises it would usher in a golden age of medicine, experts say in a debate unleashed by the looming anniversary of the first draft of the human genetic code.

The genome has yet to deliver on promises it would usher in a golden age of medicine, experts say in a debate unleashed by the looming anniversary of the first draft of the human genetic code.

On June 26 2000, two teams -- one a public consortium, the other a private venture -- tied in a frenzied, multi-billion-dollar race to be first to publish a working blueprint of .

Tens of billions of dollars have been pumped into genomics research since this landmark event.

The drive is the allure of to cure cancer, heart and and other curses.

Just as compelling: diagnostic tools to pinpoint an individual's inherited vulnerability to disease and steer the patient to hand-tailored treatments.

Yet as the anniversary nears, opinions as to what the decade has achieved coalesce around the conclusion that so far the outcome has fallen way short of a medical revolution.

"The consequences for clinical medicine... have thus far been modest," Francis Collins, who led the public-sector Human Genome Project (HGP), admits in this week's issue of Nature, the British science journal.

"Some powerful new drugs have been developed for some cancers; genetic tests can predict whether people with breast cancer need chemotherapy; the major risk factors of macular degeneration [an eye disease] have been identified; and drug response can be predicted for more than a dozen drugs.

"But it is fair to say that the Human Genome Project has not yet directly affected the health care of most individuals."

US bio-entrepreneur Craig Venter, who jousted with Collins in that epic battle 10 years ago, urges patience.

"The genome revolution is only just beginning," Venter believes.

For one thing, the cost of cracking -- "sequencing" -- a genome has fallen astonishingly, by 14,000 times between 1999 and 2009.

The (HGP) was funded with three billion dollars, or roughly a dollar for every base pair, or rung in the genetic ladder, and took 10 years to produce the rough draft, which was followed by a "polished" version in 2003.

Today, Californian companies Illumina and Life Technologies say they can do the same job in a day for less than 6,000 dollars, while rival Complete Genomics is reportedly offering a price of 5,000 dollars.

This plunge in costs has enabled scientists to prise open the DNA of a whole range of non-human species: more than 3,800 organisms, in fact, including the mouse, the fruitfly and other vital tools in lab research.

In the next decade, writes Venter, we can expect the DNA of individual sperm, egg cells, early-stage embryos, pre-tumour cells and stem cells, to see whether they are healthy or harbingers of disease.

Why does genomics seem to be taking so long to bear fruit?

One reason is that having a goldmine of data is not the same as understanding what the data mean.

And the meaning turns out to be far more complex than thought: the number of genes in an organism is not automatically the sign of its complexity, for genes and the proteins they control can have multiple roles.

With the information pool now the size of an ocean, the more urgently we need the means to be able to manipulate these data coherently -- and figuring it out.

"Now that the human has been sequenced almost completely, there is still little understanding of how genes actually work," say Monika Gisler and colleagues from ETH Zurich, a Swiss research and technology university, in the open-access journal

"(...) It is now widely recognized that it will take decades to exploit the fruits of the HGP, via a slow and arduous process aiming at disentangling the extraordinary complexity of the problem."

Those waiting for a financial return on genomics will have to wait a little bit more in what has already turned out to be a long-term bet.

As Arthur Levinson, then the chief executive of Genentech, said in March 2006: "Investors have been very patient with the biotech industry, which has been one of the biggest money-losing industries in the history of mankind."

Related Stories

Recommended for you

New methods find undiagnosed genetic diseases in electronic health records

March 15, 2018
Patients diagnosed with heart failure, stroke, infertility and kidney failure could actually be suffering from rare and undiagnosed genetic diseases.

Hundreds of genes linked to intelligence in global study

March 14, 2018
More than 500 genes linked to intelligence have been identified in the largest study of its kind. Scientists compared variation in DNA in more than 240,000 people from around the world, to discover which genes are associated ...

Study finds that genes play a role in empathy

March 12, 2018
A new study published today suggests that how empathic we are is not just a result of our upbringing and experience but also partly a result of our genes.

Large-scale genetic study provides new insight into the causes of stroke

March 12, 2018
An international research consortium studying 520,000 individuals from around the world has identified 22 new genetic risk factors for stroke, thus tripling the number of gene regions known to affect stroke risk. The results ...

Study suggests some CpGs in the genome can be hemimethylated by design

March 9, 2018
A pair of researchers at Emory University has found that some CpGs in the genome can be hemimethylated by design, rather than by chance. In their paper published in the journal Science, Chenhuan Xu and Victor Corces describe ...

Intravenous arginine benefits children after acute metabolic strokes

March 9, 2018
Children with mitochondrial diseases who suffered acute metabolic strokes benefited from rapid intravenous treatment with the amino acid arginine, experiencing no side effects from the treatment. The diseases were caused ...


Adjust slider to filter visible comments by rank

Display comments: newest first

Apr 01, 2010
This comment has been removed by a moderator.
5 / 5 (1) Apr 01, 2010
there are many computers working on this -- the issue is know what to look for. If I gave you 100 million web pages and said i need info on technology you would go to google and look it up -- but we don;t know how to define many dieases in terms of proteins or bas pairs.
not rated yet Apr 01, 2010
These specialized bioinformatics supercomputers already exist. I invented one in '91 and sold the resulting business in '03; see
5 / 5 (1) Apr 01, 2010
They also need to get over their greed and forget about patents and get the job done.
not rated yet Apr 05, 2010
anyone notice how the one comment that makes all of our replies actually make since is completely gone now -- bad moderator
not rated yet Apr 18, 2010
I think patent law is gradually catching up to the fact that it makes no sense to grant patents on natural sequence data and hand 20-year monopolies out on this basis. Sure, grant patents on specific uses and on value-added technical innovations applied to those sequences, but not to the sequences themselves.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.